Brief: Revive Therapeutics announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria
06/07/2016 13:02
July 6 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive therapeutics Ltd. announces U.S. FDA acceptance of
IND of Bucillamine for treatment of cystinuria
Source text for Eikon: ID:nMKWSzZkKa
Further company coverage: RVV.V
((Bengaluru Newsroom) ((+1 646 223 8780;)))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure